Detailed narrative
QUELIMMUNE Pediatric Market Expansion
SeaStar Medical is making significant strides in establishing QUELIMMUNE as a critical therapy for pediatric AKI and sepsis. The company has expanded its customer base to 20 of the 50 premier children's hospitals in the U.S., doubling from 10 at the beginning of 2026, and is on track to reach 25 by year-end. Recent efforts include sponsoring the Kidney B Summit and hosting an educational webinar, both aimed at increasing clinical confidence and adoption. The Centers for Medicare and Medicaid Services (CMS) assigned ICD-10-PCS codes for the SCD therapy, effective October 1, 2026, which is expected to remove a potential barrier to adoption by streamlining hospital billing.
Neutralize AKI Trial Strategy and Progress
The company is actively conducting the Neutralize AKI pivotal trial for adult patients with AKI requiring CRT, having enrolled 223 of the anticipated 339 patients. Enrollment completion is expected around year-end 2026 or Q1 2027, with the PMA submission targeted for late 2027. The trial employs a modular PMA approach and benefits from breakthrough device designation, which should expedite regulatory review. A key enrichment criterion is a C-reactive protein (CRP) level greater than 3.5 mg/dL, ensuring enrollment of patients most likely to benefit and avoiding limitations of past trials.
Financial Overview
SeaStar Medical reported Q2 FY26 net revenue of $615,000, an 82% increase over Q2 FY25, with 6-month net revenue reaching $1.1 million. The company maintained a gross profit percentage of over 90%. Operating expenses increased to $4.4 million in Q2 FY26 from $2.1 million in Q2 FY25, primarily due to increased R&D for clinical sites and enrollment, and higher G&A costs. The net loss for Q2 FY26 was $3.7 million, or $0.91 per share. Cash on the balance sheet stood at $7 million as of June 30, 2026, down from $12 million at December 31, 2025.
Long-term Vision and Pipeline
The SCD therapy, the foundational technology behind QUELIMMUNE, is first-in-class and the only immunomodulatory therapy targeting hyperactive leukocytes and monocytes. This unique mechanism positions it for broader applications beyond AKI, including cardiorenal syndrome, systemic inflammation from cardiac surgery, and chronic inflammation in end-stage renal disease, several of which have received breakthrough device designation. The adult AKI market is estimated to be 50 times larger than the pediatric market, representing a significant future opportunity.
Clinical Confidence and Real-World Use
Clinical confidence in QUELIMMUNE is growing within the pediatric critical care community, with many stories of life-saving outcomes. While new sites initially use QUELIMMUNE as a rescue therapy, mature centers are shifting towards earlier intervention, leading to even better outcomes. This broader real-world use, including patients with complex comorbidities who would not meet trial eligibility, reflects strong clinical confidence and suggests a larger addressable patient population than trial enrollment numbers alone might imply.